Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Trial Evaluating Idelalisib in Children and Adolescents With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Mediastinal B-cell Lymphoma in Combination With RICE

NCT03349346 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03349346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03349346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Trial Evaluating Idelalisib in Children and Adolescents With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Mediastinal B-cell Lymphoma in Combination With RICE
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Withdrawn
Start date
June 30, 2019
Completion date
February 28, 2026
Enrollment
0 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, mediastinal b-cell lymphoma